Cost Comparison Between Defocus Spectacle Lens and Compound Atropine in Myopia Treatment in the Portuguese Setting
Scientific Repository of Open Access of Portugal (RCAAP) · 20.09.2023
DOI: 10.48560/rspo.32886 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Repository of Open Access of Portugal (RCAAP), erschienen am 20.09.2023. Verfasst von Barros Da Silva und 4 weiteren Autor:innen.
Abstract (Originalsprache)
INTRODUCTION: The rising prevalence of myopia poses a substantial global concern. Low concentration atropine and defocus spectacle lens (DSL) are the most widely used myopia prevention treatment in Portugal. Atropine drops must be compounded in pharmacies, because there is still no commercial low concentration atropine approved in Portugal. There are no studies with enough evidence to prefer one treatment over the other, so cost might be a decisive factor. Our purpose was to compare the costs between DSL and compound atropine for myopia progression prevention in Portugal. METHODS: We collected data on compound atropine from different pharmacies in Portugal, monofocal (MF) lenses prices from the four most common brands in Portugal and DSL price from brand representatives. Cost estimates were done per year of four consecutive years of myopia prevention treatment, considering different scenarios according to the need of spectacle lens exchange. We compared costs of low dose compound atropine plus MF lens versus DSL in the different scenarios. RESULTS: Atropine treatment proved more cost-effective than DSL treatment only when there was a requirement for lens exchange every 6 months or less (609.25€ for atropine versus 780.00€ for DSL per year of treatment). When myopia progression prevention is more effective and the need of lens exchange is equal or greater than 12 months, DSL treatment showed to be less expensive than mean values of atropine treatment plus MF lens (390.00€ for DSL vs 464.59€ for atropine, per year of treatment). CONCLUSION: DSL take a cost advantage in prevention of myopia progression, in situations when there is a need of lens exchange within once a year or less frequently. However, atropine plus MF lenses might be a less expensive in cases whenever there is a need of lens exchange every 6 months or more frequently. It is essential to conduct further studies focusing on the cost-effectiveness of different treatment options for preventing myopia progression.
Schlagwörter
Zitieren
APA
Silva, B. D., Patrícia, Ludovico, I., Basílio, A. L., & Guimarães, S. (2023). Cost Comparison Between Defocus Spectacle Lens and Compound Atropine in Myopia Treatment in the Portuguese Setting. Scientific Repository of Open Access of Portugal (RCAAP). https://doi.org/10.48560/rspo.32886
Vancouver
Silva BD, Patrícia, Ludovico I, Basílio AL, Guimarães S. Cost Comparison Between Defocus Spectacle Lens and Compound Atropine in Myopia Treatment in the Portuguese Setting. Scientific Repository of Open Access of Portugal (RCAAP). 2023. doi:10.48560/rspo.32886
BibTeX
@article{Silva2023,
author = {Silva, Barros Da and Patrícia and Ludovico, Inês and Basílio, Ana Luísa and Guimarães, Sandra},
title = {Cost Comparison Between Defocus Spectacle Lens and Compound Atropine in Myopia Treatment in the Portuguese Setting},
journal = {Scientific Repository of Open Access of Portugal (RCAAP)},
year = {2023},
doi = {10.48560/rspo.32886}
}
EUVIMED